GlassScriptPhysician profile
Florence Akouegnon
NPI 1083048748
$5,051.92
in general payments reported to CMS, 2019-2025
22 companies · $2,652 in 2025
The $2,652 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $123 · 2023: $163 · 2024: $1,960 · 2025: $2,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,763 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,762.72 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $983.93 | 2023-2025 | Abilify Mycite, Rexulti |
| Neurocrine Biosciences, INC. | $797.21 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $543.59 | 2024-2025 | Caplyta |
| Alkermes, INC. | $492.12 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $386.77 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $286.31 | 2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $261.20 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $189.44 | 2024-2025 | |
| Lilly USA, LLC | $164.16 | 2023-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $157.33 | 2022-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $150.93 | 2024-2025 | Cobenfy |
| Verona Pharma, INC. | $123.61 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $119.99 | 2025 | Tyvaso |
| Horizon Therapeutics Plc | $92.71 | 2021 | |
| Braeburn INC. | $85.35 | 2023-2025 | Brixadi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $68.54 | 2024-2025 | Sublocade |
| Almatica Pharma LLC | $35.05 | 2024-2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $33.75 | 2024 | Trintellix |
| Smith+Nephew, INC. | $24.82 | 2024 | Collagenase Santyl |
| Sanofi-Aventis U.S. LLC | $18.83 | 2025 | |
| Novo Nordisk INC | $18.65 | 2023 | Wegovy |
| Janssen Pharmaceuticals, INC | $17.63 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Florence Akouegnon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.